Sargent Bickham Lagudis’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2022
Q4 | $207K | Hold |
3,060
| – | – | 0.02% | 266 |
|
2022
Q3 | $152K | Sell |
3,060
-44
| -1% | -$2.19K | 0.01% | 267 |
|
2022
Q2 | $173K | Buy |
3,104
+246
| +9% | +$13.7K | 0.02% | 264 |
|
2022
Q1 | $159K | Hold |
2,858
| – | – | 0.01% | 278 |
|
2021
Q4 | $160K | Hold |
2,858
| – | – | 0.01% | 271 |
|
2021
Q3 | $137K | Sell |
2,858
-682
| -19% | -$32.7K | 0.01% | 291 |
|
2021
Q2 | $148K | Sell |
3,540
-140
| -4% | -$5.85K | 0.01% | 296 |
|
2021
Q1 | $124K | Buy |
3,680
+168
| +5% | +$5.66K | 0.01% | 309 |
|
2020
Q4 | $123K | Buy |
3,512
+1,662
| +90% | +$58.2K | 0.01% | 301 |
|
2020
Q3 | $64K | Hold |
1,850
| – | – | 0.01% | 347 |
|
2020
Q2 | $61K | Hold |
1,850
| – | – | 0.01% | 331 |
|
2020
Q1 | $56K | Hold |
1,850
| – | – | 0.01% | 325 |
|
2019
Q4 | $54K | Hold |
1,850
| – | – | 0.01% | 371 |
|
2019
Q3 | $48K | Sell |
1,850
-2,074
| -53% | -$53.8K | 0.01% | 357 |
|
2019
Q2 | $100K | Sell |
3,924
-400
| -9% | -$10.2K | 0.01% | 283 |
|
2019
Q1 | $113K | Sell |
4,324
-580
| -12% | -$15.2K | 0.01% | 269 |
|
2018
Q4 | $113K | Hold |
4,904
| – | – | 0.01% | 253 |
|
2018
Q3 | $116K | Hold |
4,904
| – | – | 0.01% | 257 |
|
2018
Q2 | $113K | Hold |
4,904
| – | – | 0.01% | 258 |
|
2018
Q1 | $121K | Hold |
4,904
| – | – | 0.02% | 255 |
|
2017
Q4 | $132K | Hold |
4,904
| – | – | 0.02% | 253 |
|
2017
Q3 | $118K | Hold |
4,904
| – | – | 0.01% | 267 |
|
2017
Q2 | $105K | Hold |
4,904
| – | – | 0.01% | 265 |
|
2017
Q1 | $84K | Sell |
4,904
-4,642
| -49% | -$79.5K | 0.01% | 288 |
|
2016
Q4 | $171K | Buy |
9,546
+8,782
| +1,149% | +$157K | 0.03% | 213 |
|
2016
Q3 | $2.41K | Sell |
764
-131,350
| -99% | -$414K | 0.36% | 76 |
|
2016
Q2 | $3.55M | Buy |
132,114
+6,040
| +5% | +$162K | 0.55% | 53 |
|
2016
Q1 | $3.42M | Buy |
+126,074
| New | +$3.42M | 0.55% | 56 |
|